Personalized Medicine in Ovarian Cancer: A Perspective From Mexico

被引：5

作者：

Fernandez-Garza, Luis E. ^{[1
]}

Dominguez-Vigil, Irma G. ^{[2
]}

Garza-Martinez, Jose ^{[3
]}

Valdez-Aparicio, Erick A. ^{[1
]}

Barrera-Barrera, Silvia A. ^{[4
]}

Barrera-Saldana, Hugo A. ^{[1
,5
]}

机构：

[1] Innbiogem SC Vitagenesis SA, Natl Lab Serv Res Dev & Innovat Pharma & Biotech, CONACyT Vitaxentrtun Grp, Monterrey, Nuevo Leon, Mexico

[2] Nuvance Hlth, Lab Translat Res, Rudy L Ruggles Biomed Res Inst, Danbury, CT USA

[3] Tecnol Monterrey, Monterrey, Nuevo Leon, Mexico

[4] Natl Inst Pediat, Mexico City, DF, Mexico

[5] Natl Polytech Inst, Ctr Genom Biotechnol, Reynosa, Tamaulipas, Mexico

来源：

WORLD JOURNAL OF ONCOLOGY | 2021年 / 12卷 / 04期

关键词：

Personalized medicine; Ovarian cancer; Targeted therapies; Mexico; NEOADJUVANT CHEMOTHERAPY; EPITHELIAL OVARIAN; MUTATIONS; BRCA1;

D O I：

10.14740/wjon1383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer (OC) represents a serious health problem worldwide. In Mexico, most OC patients are detected at late stages, consequently making OC one of the leading causes of death in women after reaching puberty. Personalized medicine (PM) provides an individualized therapeutic opportunity for treating each patient relying on "omic" tools to match the correct drug with the specific pathogenic genomic signature. PM can help predict the best therapeutic option for each affected woman suffering from OC. In recent years, Mexico has made contributions to the PM of OC; however, it still has a long way to go for its full implementation in the country's health system.

引用

页码：85 / 92

页数：8

共 50 条

[1] Implications of personalized medicine—perspective from a cancer center
Thomas Tursz
Fabrice Andre
Vladimir Lazar
Ludovic Lacroix
Jean-Charles Soria
[J]. Nature Reviews Clinical Oncology, 2011, 8 : 177 - 183
[2] Ovarian Cancer Immunotherapy and Personalized Medicine
Morand, Susan
Devanaboyina, Monika
Staats, Hannah
Stanbery, Laura
Nemunaitis, John
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
[3] Implications of personalized medicine-perspective from a cancer center
Tursz, Thomas
Andre, Fabrice
Lazar, Vladimir
Lacroix, Ludovic
Soria, Jean-Charles
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (03) : 177 - 183
[4] Biomarkers in Ovarian Cancer: Towards Personalized Medicine
Lopez-Portugues, Carlos
Montes-Bayon, Maria
Diez, Paula
[J]. PROTEOMES, 2024, 12 (01)
[5] Personalized Medicine for Primary Treatment of Serous Ovarian Cancer
Longo, Dan L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2471 - 2474
[6] Disparity in the era of personalized medicine for epithelial ovarian cancer
Devlin, Michael-John
Miller, Rowan E.
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[7] Educating for Personalized Medicine: A Perspective From Oncology
Parkinson, D. R.
Ziegler, J.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) : 23 - 25
[8] From personalized to precision cancer medicine
Baltagiannis, Evangelos G.
Kyrochristos, Ioannis D.
Ziogas, Demosthenes E.
Goussia, Anna
Mitsis, Michail
Roukos, Dimitrios H.
[J]. PERSONALIZED MEDICINE, 2020, 17 (04) : 245 - 250
[9] FROM PHARMACOGENETICS TO PERSONALIZED MEDICINE: A CUBAN REGULATORY PERSPECTIVE
Remirez, D.
[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 83 - 83
[10] CYTOKERATIN 19 AND ITS PERSPECTIVE IN PERSONALIZED MEDICINE OF BREAST CANCER
Topolcan, O.
Svobodova, S.
Kinkorova, J.
Pesta, M.
Fiala, O.
Fuchsova, R.
Treska, V.
[J]. ANTICANCER RESEARCH, 2014, 34 (11) : 6847 - 6847

← 1 2 3 4 5 →